Alan D'Andrea

Has grant

Director, Center for DNA Damage and Repair

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Extending the use of PARP Inhibitors for Triple Negative Breast Cancer Therapy

Open Date: 2024-10-01

Close Date: 2025-09-30

Grant: Close

Extending the Use of PARP Inhibitors for Triple Negative Breast Cancer

Open Date: 2022-10-01

Close Date: 2023-09-30

Grant: Close

Combination of Bortezomib plus PARP Inhibitor for Triple Negative Breast Cancer Therapy

Open Date: 2014-10-01

Close Date: 2015-09-30

Grant: Close

Combination of Bortezomib plus PARP inhibitor for Triple Negative Breast Cancer Therapy: Murine Preclinical Studies

Open Date: 2013-07-26

Close Date: 2018-02-22

Articles (29)

Purpose: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2–mutated HER2-negative metastatic breast cancer. Patients and Methods: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor–naïve were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to IHC for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for ctDNA analysis. Results: Ten patients (3 BRCA1 and 7 BRCA2) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 50% (95% confidence interval, 18.7%–81.3%), with median progression-free survival (mPFS) of 9.7 months (95% confidence interval, 8.02–not estimable). Three patients had clinical benefit greater than 15 months, including two who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from two patients had evidence of BRCA reversion mutations associated with a microhomology-mediated end-joining signature, and three patients had acquired putative nonreversion mechanisms of resistance. Conclusions: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.

Year:

2026

Year:

2026

Year:

2026

The proliferating cell nuclear antigen (PCNA) sliding clamp is a central component of eukaryotic DNA synthesis. In response to DNA damage, PCNA is mono-ubiquitinated by the RAD6 (E2)-RAD18 (E3) complex. However, the structural basis by which RAD18 engages PCNA to direct mono-ubiquitination has remained poorly defined. Mono-ubiquitinated PCNA can subsequently be extended with K48-linked poly-ubiquitin chains that target PCNA for degradation. Ubiquitin-specific protease 1 (USP1) reverses both mono- and poly-ubiquitination of PCNA; accordingly, USP1 inhibition promotes accumulation of mono-ubiquitinated PCNA at replication forks and reduces total PCNA levels, leading to replication defects that are synthetically lethal with BRCA1 deficiency. Here, we combine computational and structural approaches to identify and characterize a SAP domain PCNA-interacting peptide (PIP) motif within RAD18. We demonstrate that this interaction is required for DNA damage-induced PCNA mono-ubiquitination and for PCNA turnover following USP1 loss. Disruption of the RAD18-PCNA interface suppresses ssDNA gap accumulation and reduces USP1 inhibitor sensitivity in BRCA1-deficient cells. Furthermore, cells adapted to prolonged USP1 inhibition exhibit reduced RAD18 levels, suggesting that deregulation of PCNA mono-ubiquitination represents a biologically relevant resistance mechanism. Together, these findings define a structural interface required for RAD18-dependent PCNA mono-ubiquitination and establish it as a key determinant of USP1-BRCA1 synthetic lethality.

Year:

2026

Purpose: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2– mutated HER2-negative metastatic breast cancer. Patients and Methods: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor–naïve were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to IHC for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for ctDNA analysis. Results: Ten patients (3 BRCA1 and 7 BRCA2 ) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 50% (95% confidence interval, 18.7%–81.3%), with median progression-free survival (mPFS) of 9.7 months (95% confidence interval, 8.02–not estimable). Three patients had clinical benefit greater than 15 months, including two who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from two patients had evidence of BRCA reversion mutations associated with a microhomology-mediated end-joining signature, and three patients had acquired putative nonreversion mechanisms of resistance. Conclusions: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.

Year:

2026

Year:

2025

Year:

2025

Background: TOPACIO was a phase I/II study evaluating the PARP inhibitor (PARPi) niraparib in combination with the anti-PD-1 antibody pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer (TNBC, n=55), irrespective of BRCA status. In the efficacy-evaluable population (n=47) the objective response rate (ORR) was 21% and disease control rate (DCR) 49%. Although activity was greater in BRCA-MUT patients (7/15, ORR=47% and 12/15, DCR=80%), durable clinical benefit was seen in patients with BRCA-WT tumors (3/27, ORR=11% and 9/27, DCR=33%). Patients with PD-L1+ tumors (28/47, 60%) achieved higher ORR (9/28, 32%) than those with PD-L1neg tumors (1/13, 8%). It remains unstudied whether tumor gene expression or immune composition in baseline biospecimens is predictive of treatment response. We conducted exploratory biomarker analyses to uncover gene expression patterns and immune states associated with treatment response. Methods: Transcriptional profiling of baseline samples was performed using the BC360 (n=41) and PanCancer IO360 (n=42) panels (Nanostring) and multigene signatures were used to measure tumor and immune activities. Transcriptional analysis was paired with high-dimensional, single-cell cyclic immunofluorescence (CyCIF) of samples with adequate tissue for analysis (n=22) to characterize the immune microenvironment at single-cell resolution. Results: BRCA-MUT tumors showed increased downstream interferon signaling and immune infiltration relative to BRCA-WT tumors (p < 0.05). Downstream interferon and immunoproteasome scores were elevated in objective responders (p < 0.05). Genes involved in WNT signaling (TANKS1, TANKS2, PARP4, and NETO2) associated with long-term response, defined by those still on therapy and responding at data cut off. Low NETO2 gene expression strongly associated with better ORR (p = 0.01). CyCIF analysis performed on whole tissue sections accounting for 2.97x106 single cells revealed that in BRCA-WT patients, baseline infiltration of immune cells - cells expressing CD45, CD3 (T cells), CD20 (B cells) or CD68/CD163 (macrophages) positively correlated with favorable PFS (R=0.81, p=0.0004, Spearman’s correlation). Further, increasing fractions of CD8+ and PD-1+ CD4+ T cells strongly associated with favorable PFS (R > 0.71, p < 0.0041). In BRCA-MUT patients, baseline immune composition did not correlate with clinical outcome. Conclusions: NETO2 expression, WNT pathway, and interferon signaling associate with response to niraparib plus pembrolizumab. While BRCA-MUT tumors showed higher baseline immune cell abundance compared to BRCA-WT, immune and T cell infiltration was predictive of PFS duration only in BRCA-WT patients, suggesting divergent mechanisms of response to PARPi and ICB dependent on BRCA status. Citation Format: Alexander P. Gottlieb, Gregory J. Baker, Jia-Ren Lin, Ricardo Pastorello, Yu-An Chen, Tuulia Vallius, Janae Davis, Clarence Yapp, Sarah E. Church, Eric Miller, Anniina Farkkila, Shaveta Vinayak, Melinda L. Telli, Sara M. Tolaney, Filipa Lynce, Joan S. Brugge, Alan D'Andrea, Geoffrey Shapiro, Sandro Santagata, Peter K. Sorger, Elizabeth A. Mittendorf, Jennifer L. Guerriero. High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7152.

Year:

2025

BRCA1-deficient tumors are unable to efficiently perform DNA repair by homologous recombination (HR) and are dependent on alternative DNA damage response pathways. PARP inhibitors have improved the progression-free survival of HR-deficient ovarian cancer patients in clinical settings. However, PARP inhibitor (PARPi) resistance often develops, and new therapies are required for these patients. USP1 is a deubiquitinating enzyme that controls DNA repair pathways through the deubiquitination of PCNA-Ub and the activation of Translesion DNA Synthesis (TLS). Inhibitors of USP1 result in a strong upregulation of PCNA-Ub levels and a dysregulation of TLS repair. Importantly, USP1 is synthetically lethal in BRCA1-deficient tumors (Lim et al., Mol Cell, 2018), and USP1 inhibitors (USP1is) are currently undergoing clinical development for the treatment of these cancers as monotherapy or in combination with a PARPi. USP1is kill BRCA1-mutated patient-derived ovarian cancer organoids (PDOs) and overcome PARPi resistance in BRCA1-WT PDOs (da Costa et al, Cancer Research, 2024). Sensitivity to USP1i strongly correlates with the accumulation of single strand DNA (ssDNA) gaps in both PARPi-sensitive and PARPi-resistant PDOs. Moreover, knockdown of RAD18, the E3 ubiquitin ligase required for PCNA ubiquitination, results in a reduction in PCNA-Ub levels and a corresponding reduction in ssDNA gaps, and in USP1i resistance. These findings suggest that ssDNA gaps and RAD18 levels in the tumors can predict the sensitivity to USP1 inhibitors. As BRCA1-mutated tumors express high levels of USP1 mRNA, we also investigated the relevance of this biomarker in predicting the sensitivity to USP1 inhibitors. Interestingly, the USP1i sensitivity correlated with increased USP1 mRNA expression, at baseline, in ovarian cancer PDO and patient-derived xenograft-derived organoid (PDXO) models. Similar results were obtained in BRCA1-deficient breast cancer cell line models with acquired PARPi resistance. USP1i sensitive ovarian cancer organoid models retained high USP1 mRNA levels upon PARPi treatment. The specific organoid models that were resistant to PARPi or USP1i monotherapy exhibited up to 40-fold increase in expression of USP1 mRNA and they were sensitive to a combination of USP1i plus PARPi. Taken together, in addition to the accumulation of ssDNA gaps and RAD18 levels, the relative expression of USP1 mRNA is a useful prognostic biomarker for patients who may respond to USP1 inhibitors, either as monotherapy or in combination with PARP inhibitors. These predictive biomarkers will be useful in monitoring the response of ovarian cancer patients enrolled in USP1i plus PARPi clinical trials. Citation Format: Ozge Somuncu, Nicholas Ashton, Alexandre A. B. A. da Costa, Sirisha Mukkavalli, Ramya Ravindranathan, Benjamin Lamarre, Huy Nguyen, Lisa Moreau, Joyce Liu, Geoffrey I. Shapiro, Kalindi Parmar, Alan D. D’Andrea. Identification of predictive biomarkers of USP1 inhibitor sensitivity using ovarian cancer organoid models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4004.

Year:

2025

Recent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatment is based on the premise that AR directly regulates expression of DNA repair genes, leading to synergy between PARP and AR inhibition. Despite some promising preclinical evidence, this combination therapy has shown limited efficacy in patients with homologous recombination (HR)-proficient tumors. To investigate this discrepancy between preclinical and clinical results, we profiled the effects of PARP inhibition in prostate cancer models in the presence or absence of AR inhibition. Surprisingly, AR inhibition impaired response to PARP inhibitors in castration-sensitive cells and had no effect on response in castration-resistant cells. AR inhibition also did not regulate DNA repair in either the castration-resistant or castration-sensitive setting. Instead, we find that cell cycle progression is required for response to PARP inhibition in homologous-recombination proficient prostate cancer. STATEMENT OF SIGNIFICANCE Androgen deprivation does not inhibit DNA repair and does not synergize with PARP inhibition in prostate cancer with intact homologous recombination repair.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (22)

Bose Kochupurakkal

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Nicholas William Ashton

Senior Scientist

University of Kansas Medical Center

UNITED STATES
View details

David Kolin

Brigham and Women's Hospital

UNITED STATES
View details

Tianpeng Zhang

Assistant Professor

University of Virginia

UNITED STATES
View details

Mona Batish

Associate Professor

University of Delaware

UNITED STATES
View details

Dávid Szüts

Principal Intestigator

Research Centre for Natural Sciences

HUNGARY
View details

Nathalie Agar

Principal Investigator

Brigham and Women's Hospital

UNITED STATES
View details

Irina Bezsonova

Associate Professor

University of Connecticut Health Center

UNITED STATES
View details

Judy Garber

Chief, Division of Cancer Genetics and Prevention

Dana-Farber Cancer Institute

UNITED STATES
View details

Madeline Polak

Dana-Farber Cancer Institute

UNITED STATES
View details

Feng Li

Dana-Farber Cancer Institute

UNITED STATES
View details

Brittany Bychkovsky

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Huy Nguyen

Dana-Farber Cancer Institute

UNITED STATES
View details

Aleem Syed

Dana-Farber Cancer Institute

UNITED STATES
View details

Yuqing Jiao

Dana-Farber Cancer Institute

UNITED STATES
View details

Carlos Torrado

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Bartlomiej Tomasik

Medical University of Gdansk

POLAND
View details

Filipa Lynce

Dana-Farber Cancer Institute

UNITED STATES
View details

Sirisha V Mukkavalli

Senior Scientist/Lab Manager

Dana-Farber Cancer Institute

UNITED STATES
View details

István Csabai

-

HUNGARY
View details

Roger Greenberg

Professor

University of Pennsylvania

UNITED STATES
View details